Knowledge HQ

Due to supply chain shortages, the authors validated G-Rex vessels as an alternative to Wave bioreactors for CAR T expansion. G-Rex 1L vessels produced 2-4 billion T cells with >90% viability and comparable phenotype/function, using significantly less media and labor than the Wave system.

This paper presents a scalable platform for allogeneic T cell manufacturing using stirred-tank bioreactors (STR) with perfusion. It compares STR performance to G-Rex, noting that while G-Rex achieved 28-fold expansion, the perfused STR achieved 167-fold expansion, demonstrating superior scalability.

The authors describe a robust method for expanding Vd1 gamma-delta T cells using OKT-3 and IL-15. Culture in 6-well G-Rex vessels supported >1000-fold expansion in some donors. The expanded Vd1 cells were efficiently transduced with CARs and demonstrated potent antigen-specific cytotoxicity.

This protocol details the manufacturing of CAR Tregs for non-human primates. G-Rex 6-well plates were used to expand K562 artificial antigen-presenting cells (aAPCs), which were subsequently used to stimulate Tregs. The method yields highly suppressive CAR Tregs for pre-clinical studies.

The study identified IL-15 + IL-7 as the optimal cytokine cocktail for expanding SARS-CoV-2-specific T cells (CSTs). Results were translated to a GMP-applicable format using G-Rex 10, which showed improved expansion and specificity, particularly for CD8+ T cells, compared to IL-4 + IL-7.

This article evaluates TAK-186, a protease-activated T cell engager. Human T cells used for in vivo efficacy studies were expanded using G-Rex 100. TAK-186 demonstrated regression of EGFR+ solid tumors in mice, validating the conditional activation design in a tumor microenvironment.

This study monitored anti-CAR antibody responses in rhesus macaques infused with CD4-MBL CAR/CXCR5 T cells. The therapeutic cells were expanded in G-Rex 6-well plates prior to infusion. All treated animals developed anti-CAR antibodies, which correlated with limited in vivo persistence of the CAR T cells.

This poster presents a G-Rex-based method for expanding lentiviral transduced HSPCs to determine vector copy number (VCN). Compared to standard plates, G-Rex cultures showed higher expansion rates, high viability, and similar lineage phenotypes, providing a less laborious and cost-effective method for QC testing.

This study evaluates the impact of cryopreservation on CAR T cell production. Cells were expanded in G-Rex100, which facilitated simple media top-ups. The study found that cryopreserved PBMCs and CAR T products yielded comparable expansion and clinical responses to fresh materials.

The authors describe a method to generate TCR and CD8ab transgenic VSTs using IFN-g cytokine capture. G-Rex devices were utilized for the second stimulation expansion phase, yielding high numbers of polyfunctional T cells with simultaneous anti-viral and anti-tumor activity in a shortened timeframe.

This paper presents AsCas12a Ultra, an engineered nuclease with high editing efficiency. G-Rex technology was used to expand human CD3+ T cells and activate NK cells during the editing workflows. The nuclease enabled robust multiplex editing and transgene knock-in in various primary cell types.

The authors engineered high-potency CARs targeting HPV E6 peptide-MHC complexes. Primary T cells transduced with these CARs were expanded in 24-well G-Rex plates supplemented with IL-2. The optimized CARs showed comparable sensitivity and selectivity to clinical TCRs in cytotoxicity assays.